Skip to content

About Us
Science & Platform
News & Media
Join Us
Contact Us

News & Media

Press Releases

ImmuneID Appoints Jessica Atkinson as Chief Business Officer
October 17, 2022

ImmuneID Announces Appointment of Pam Stetkiewicz, Ph.D., to Board of Directors
July 12, 2022

ImmuneID Announces Key Partnerships with Icahn School of Medicine at Mount Sinai and University Hospital Erlangen to Advance Novel Immune System Insights
March 31, 2022

ImmuneID Appoints Jeremiah Degenhardt, Ph.D., as SVP Computational Biology
February 1, 2022

ImmuneID Appoints Veteran Biotech Executive James S. Scibetta as CEO
September 21, 2021

ImmuneID Announces Close of $50 Million Series A Financing to Develop Precision Immunology Therapeutics
June 23, 2021

ImmuneID Appoints Annalisa D’Andrea as President and Chief Scientific Officer
April 5, 2021

ImmuneID Launches with $17M Financing to Profile and Modulate Immune Response at Unprecedented Scale and Resolution
February 17, 2021

In The News

Stephen Elledge’s Harvard lab takes $17M to birth ImmuneID, a high-throughput antibody startup
February 17, 2021

Longwood Fund-backed precision immunology startup launches with $17M
February 17, 2021

Publications

Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
January 13, 2022

High-resolution epitope mapping reveals interplay between IgE and IgG repertoires during peanut oral immunotherapy
October 19, 2021

Profiling serum antibodies with a pan allergen phage library identifies key wheat allergy epitopes
2021

Citrullination of a phage-displayed human peptidome library reveals the fine specificities of rheumatoid arthritis-associated autoantibodies
2021

Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity
October 23, 2020

A viral exposure signature defines early onset of hepatocellular carcinoma
July 23, 2020

Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens
November 3, 2019

Comprehensive serological profiling of human populations using asynthetic human virome
June 9, 2015

Contact Us

275 Second Ave, Suite 100
Waltham, MA 02451
info@immuneidrx.com

©2022 ImmuneID, Inc.
Privacy Policy Terms of Service

James S. Scibetta

Chief Executive Officer

Mr. James S. Scibetta joined ImmuneID as Chief Executive Officer in September 2021, bringing over 20 years’ experience successfully leading life science companies from early-stage platform development through commercialization. Jim also currently serves on the Board of Aquestive Therapeutics and Matinas BioPharma. Before ImmuneID, Jim served as CEO and member of the Board of Directors for Maverick Therapeutics prior to its acquisition by Takeda in April 2021. Jim previously held various executive leadership roles at Pacira Pharmaceuticals, including President and CFO, where he successfully led the company’s 2011 IPO and subsequent debt and equity financings. Prior to Pacira, Jim served as CFO of Bioenvision and Merrimack Pharmaceuticals. He began his career in investment banking, spending over a decade sourcing and executing transactions for a range of public and private healthcare and life sciences companies. Jim holds a BS in physics from Wake Forest University and an MBA from the University of Michigan.

Jeff Capello

CFO/COO

BS University of Vermont
MBA Harvard Business School

Mr. Jeff Capello is a senior finance executive with over 30 years of experience helping companies create significant value for their shareholders. Mr. Capello started his career in public accounting with PricewaterhouseCoopers where he was an audit partner on a variety of assignments ranging from helping startup companies through the public offering process to helping larger companies with strategic, transaction and operational support projects. He also served as the Chief Financial Officer for a range of publicly held and private equity backed companies (PerkinElmer, Boston Scientific, Ortho Clinical Diagnostic, Beacon Health Options and Biogen) where he developed a strong record of improving the operational and financial health of these organizations. Mr. Capello’s specific areas of expertise include strategic planning, business development, capital markets, business planning, cost management, productivity improvement, functional leadership, people development and organizational design. He also served on the Board of Directors for several early stage publicly held biotech companies as Audit Committee Chair. Mr. Capello has a Master’s in Business Administration from the Harvard Business School and a Bachelor of Science in Business Administration. He also was a Certified Public Accountant in Massachusetts.

Ittai Harel

Managing Partner, Pitango Healthtech Fund

Mr. Ittai Harel serves on ImmuneID’s Board of Directors and is the Managing Partner at Pitango Healthtech Fund. He also currently serves on the Board of Directors of DouxMatok, EarlySense, Medisafe, Clew Medical, Tscan, Vertos Medical, Visby Medical and is Chairman at EarlySense. His investments focus on digital health, health-IT and med tech, and he has over 15 years of experience in venture capital and 20 years of experience in operations and management roles. Before joining Pitango, Ittai headed Corporate Development at Nektar Therapeutics, served as Executive Vice President roles at IDGene Pharmaceuticals and IDEXX Laboratories. Ittai holds a BSc in chemical engineering and biotechnology from Ben-Gurion University, and an MBA from the MIT Sloan School of Management.

Steve Kafka, PhD

Managing Partner, Section 32

Dr. Steve Kafka serves on ImmuneID’s Board of Directors and is the Managing Partner of Section 32, where he led Section 32’s investments in C2i Genomics, CelsiusTx and Glympse Bio (where he serves as Executive Chairman). Steve works with exceptional scientists and entrepreneurs to help build companies that seek to create vast improvements in patient care and rewarding professional opportunities for employees. Prior to Section 32, Steve held leadership roles with several biotechnology companies including Thrive Early Detection, where he co-led investment and served as both founding CEO and Executive Chairman of Thrive Earlier Detection, ArcherDX, where he served as Executive Chairman, and Foundation Medicine, where he was President and Chief Operating Officer. Steve holds a PhD degree in political economy and government from Harvard University and a BA degree in economics and political science from Stanford University.

Dan Janney

Managing Partner, Alta Partners

Mr. Dan Janney serves on ImmuneID’s Board of Directors and is the Managing Partner of Alta Partners. Dan has nearly 25 years of successful early-stage investing experience in life sciences and his focus on working with talented entrepreneurs to create companies around novel insights in biology and new approaches to drug discovery has led to the funding and development of 35 companies. Prior to Alta, Dan was a senior investment banker at Montgomery Securities. Dan currently serves on the Board of Directors of several public and private companies, including Allakos, Be Biopharma, Curasen Therapeutics, Krystal Biotech, Lassen Therapeutics, Novome Biotechnologies and Prolacta Bioscience. He is also a member of The President’s Council of the J. David Gladstone Institutes, Chair of the Board of Directors of the California Academy of Sciences and serves on the Board of Regents of Georgetown University. Dan holds a BA from Georgetown University and an MBA from the Anderson School at the University of California, Los Angeles.

About Us
Science & Platform
News & Media
Join Us
Contact Us